Developing precision medicines for kidney diseases
Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases.
News & HIGHLIGHTs
Visit our news page for the latest press releases
January 12, 2022
Download the latest Chinook Corporate Presentation
The atrasentan phase 3 ALIGN clinical trial is enrolling patients with IgA nephropathy and the atrasentan phase 2 AFFINITY clinical trial is enrolling patients with proteinuric glomerular diseases.
Advancing a pipeline of precision medicines for kidney diseases.
Our lead pipeline candidates target rare, severe kidney disorders with few currently approved therapies.
May 24, 2022
Chinook Therapeutics Announces Pricing of a $105 Million Public Offering